Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

NCT07159217 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer
Disitamab Vedotin
Lenvatinib
Immune Checkpoint Inhibitors

Interventions

DRUG: Disitamab Vedotin
DRUG: Lenvatinib
DRUG: Pembrolizumab
DRUG: Toripalimab
DRUG: Camrelizumab

Sponsor

Peking Union Medical College Hospital